natgillin/translations-raw huggingface dataset:
On combining the data from phase III monotherapy and adjunctive LUMIGAN 0.3 mg/ml eye drops, solution usage, the most frequently reported treatment-related adverse events were: growth of eyelashes in up to 45% in the first year with the incidence of new reports decreasing to 7% at 2 years and 2% at 3 years, conjunctival hyperaemia (mostly trace to mild and thought to be of a noninflammatory nature) in up to 44% in the first year with the incidence of new reports decreasing to 13% at 2 years and 12% at 3 years and ocular pruritus in up to 14% of patients in the first year with the incidence of new reports decreasing to 3% at 2 years and 0% at 3 years. 
S kombinacijo podatkov iz III. faze monoterapije in adjuvantne terapije z zdravilom LUMIGAN 0,3 mg/ml kapljice za oko, raztopina, so bila najpogostejša poročila o neželenih učinkih, kot posledica zdravljenja: rast trepalnic pri do 45 % bolnikov v prvem letu, z upadom števila novih poročil na 7 % pri 2 letih in 2 % pri 3 letih, hiperemija veznice (najpogosteje komaj opazna do blaga in domnevno nevnetnega izvora) pri do 44 % bolnikov v prvem letu, z upadom števila novih poročil na 13 % pri 2 letih in na 12 % pri 3 letih in okularni puritus pri do 14 % bolnikov v prvem letu, z upadom števila novih poročil na 3 % pri 2 letih in 0 % pri 3 letih.
EXP Once the pouch is opened, the single dose containers should be used within 30 days. 
EXP Ko je vrečka odprta, enoodmerne vsebnike porabite v 30 dneh.
Carton containing 30 or 90 single-dose containers in three or nine aluminium foil pouches, respectively. 
Škatla, ki vsebuje 30 ali 90 enoodmernih vsebnikov v treh ali devetih vrečkah iz aluminijaste folije.
4 weeks after first opening. 
4 tedne po prvem odprtju.
Fertility There are no data on the effects of bimatoprost on human fertility. 
Plodnost Ni podatkov o učinkih bimatoprosta na plodnost pri ljudeh.
Take one single-dose container from the pouch and hold it upright (with the cap pointing upwards) and twist off the cap. 
Vzemite en enoodmerni vsebnik iz vrečke ter ga držite pokončno (da je pokrovček obrnjen navzgor) in pokrovček odstranite tako, da ga zasukate.
Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. 
V nekliničnih študijah so zabeležili učinke le pri izpostavljenosti, ki naj bi znatno presegala maksimalno izpostavljenost pri človeku, kar kaže, da je to za klinično uporabo manj pomembno.
Wait 15 minutes after using the drops, and before you put your lenses back in. 
Po uporabi kapljic počakajte 15 minut, preden si ponovno vstavite leče.
These doses resulted in systemic exposures of at least 33- or 97-times higher, respectively, than the intended human exposure. 
Pri teh odmerkih je prišlo do najmanj 33- oz. 97-krat večje sistemske izpostavljenosti kot pri priporočeni uporabi pri človeku.
Affecting the body 
Učinki na telo:
The mechanism of action by which bimatoprost reduces intraocular pressure in humans is by increasing aqueous humour outflow through the trabecular meshwork and enhancing uveoscleral outflow. 
Mehanizem delovanja, s katerim bimatoprost znižuje zvišan očesni tlak pri ljudeh, je s povečanjem iztekanja prekatne vodice skozi trabekularno omrežje in povečanje uveoskleralnega iztekanja.
As with any ocular treatment, if transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machines. 
Tako kot pri ostalih zdravljenjih oči morajo bolniki, če se jim po vkapanju pojavi začasno zamegljen vid, počakati z vožnjo ali upravljanjem s stroji, dokler se vid ne zbistri.
Iris colour changes seen with ophthalmic administration of bimatoprost may not be noticeable for several months to years. 
Spremembe barve irisa ob uporabi bimatoprosta lahko ne zaznamo nekaj mesecev ali let.
If you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
LUMIGAN has not been studied in patients with heart block more severe than first degree or uncontrolled congestive heart failure. 
Zdravila LUMIGAN niso preučevali pri bolnikih z obliko srčne blokade težjo kot prve stopnje ali pri nekontroliranem kongestivnem srčnem popuščanju.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1.
To help prevent infections and avoid eye injury, do not let the tip of the bottle touch your eye or anything else. 
Da bi preprečili okužbe in poškodbe očesa pazite, da se z vrhom kapalke ne dotaknete očesa ali česarkoli drugega.
• Symptoms of allergic reaction (swelling, redness of the eye and rash of the skin) 
• simptomi alergijske reakcije (oteklina, rdečina očesa in kožni izpuščaj)
- You have or have had low blood pressure or low heart rate - You have had a viral infection or inflammation of the eye 
- če imate ali ste imeli nizek krvni tlak ali počasen srčni utrip, - če ste imeli virusno okužbo ali vnetje očesa.
The increased iris pigmentation appears to be caused by increased stimulation of melanin production in melanocytes and not by an increase in melanocyte number. 
Povečanje pigmentacije irisa je kot kaže povzročeno s povečano stimulacijo tvorbe melanina v melanocitih in ne zaradi povečanega števila melanocitov.
However, once the pouch is opened use within 30 days. 
Vendar ga morate po odprtju vrečke porabiti v 30 dneh.
Bimatoprost is eliminated primarily by renal excretion, up to 67 % of an intravenous dose administered to healthy adult volunteers was excreted in the urine, 25 % of the dose was excreted via the faeces. 
Do 67 % vnesenega intravenskega odmerka zdravim odraslim prostovoljcem je bilo izločeno z urinom, 25 % odmerka je bilo izločeno z blatom.
• An increase in blood-test results that show how your liver is working 
• zvišane vrednosti kazalcev v krvi, ki kažejo delovanje jeter.
Since LUMIGAN contains benzalkonium chloride, monitoring is required with frequent or prolonged use in dry eye patients or where the cornea is compromised. 
Ker zdravilo LUMIGAN vsebuje benzalkonijev klorid, je pri pogosti ali podaljšani uporabi potreben nadzor pri bolnikih s suhimi očmi ali kjer je okvarjena roženica.
No functional or microscopic changes related to the periocular effects were observed, and the mechanism of action for the periocular changes is unknown. 
Funkcionalnih ali mikroskopskih sprememb, povezanih s periokularnimi učinki, ni bilo opaziti.
Pack contains 3 or 9 aluminium foil pouches, each containing 10 single-dose containers, for a total of 30 or 90 single-dose containers in a carton, respectively. 
Pakiranje vsebuje 3 ali 9 vrečk iz aluminijaste folije, od katerih vsaka vsebuje 10 enoodmernih vsebnikov, tako da je v posamezni škatli 30 ali 90 enoodmernih vsebnikov.
Other side effects reported with eye drops containing phosphates. 
Drugi neželeni učinki kapljic za oko, ki vsebujejo fosfate.
• Asthma 
• astma,
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Other medicines and LUMIGAN 0.3 mg/mL single-dose Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. 
Druga zdravila in zdravilo LUMIGAN 0,3 mg/ml (enoodmerna oblika) Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
• Worsening of vision 
• poslabšanje vida,
Patients using LUMIGAN with other prostaglandin analogues should be monitored for changes to their intraocular pressure. 
Pri bolnikih, ki zdravilo LUMIGAN uporabljajo z drugimi analogi prostaglandina, je treba spremljati spremembe očesnega tlaka.
• Skin discoloration (periocular) 
• sprememba barve kože (periokularno).
Remove contact lenses before use. 
Pred uporabo odstranite kontaktne leče.
Co. Mayo Ireland 
Westport Co. Mayo Irska
This medicinal product does not require any special storage conditions. 
Za to zdravilo niso potrebni posebni pogoji shranjevanja.
- The active substance is bimatoprost. 
- Učinkovina je bimatoprost.
To avoid contamination, do not let the open-end of the single-dose container touch your eye or anything else. 
Da bi preprečili okužbo, pazite, da se z vrhom enoodmernega vsebnika ne dotaknete očesa ali česarkoli drugega.
If you are pregnant or breast feeding, think you might be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking any medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete katerokoli zdravilo.
Always use this medicine exactly as your doctor or pharmacist has told you. 
Zdravilo uporabljajte vedno natančno po navodilih zdravnika ali farmacevta.
If the high pressure is not reduced, it could lead to a disease called glaucoma and eventually damage your sight. 
Če visokega tlaka ne zmanjšamo, lahko pride do bolezni, ki ji pravimo glavkom, ter posledično do poškodbe vida.
If you use LUMIGAN with another eye medicine, wait at least five minutes between using LUMIGAN and the other eye medicine. 
Če poleg zdravila LUMIGAN uporabljate še druga zdravila za oko, med uporabo zdravila LUMIGAN in drugega zdravila za oko počakajte vsaj 5 minut.
Patients with COPD, asthma or compromised respiratory function due to other conditions should be treated with caution. 
Bolnike s kronično obstruktivno pljučno boleznijo, astmo ali oslabelim delovanjem respiratornega sistema zaradi drugih bolezenskih stanj je treba zdraviti previdno.
Make sure that the single-dose container is intact before use. 
Prepričajte se, da je enoodmerni vsebnik nepoškodovan.
Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts become more brownish. 
Rjava pigmentacija okoli zenice se v prizadetem očesu običajno koncentrično razširi proti periferiji irisa, ki postane v celoti ali delno bolj rjav.
LUMIGAN should not be used during pregnancy unless clearly necessary. 
Če ni nujno potrebno, zdravila LUMIGAN med nosečnostjo ni dovoljeno uporabljati.
Do not use this medicine: - If you are allergic to bimatoprost or any of the other ingredients of this medicine (listed in section 6). 
Ne uporabljajte tega zdravila: - Če ste alergični na bimatoprost ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Since LUMIGAN 0.1 mg/ml contains 200 ppm benzalkonium chloride (four times the concentration in bimatoprost 0.3 mg/ml eye drops), it should be used with caution in dry eye patients, in patients where the cornea may be compromised and in patients taking multiple BAK-containing eye drops. 
Ker zdravilo LUMIGAN 0,1 mg/ml vsebuje 200 ppm benzalkonijevega klorida (štirikrat večja koncentracija kot v bimatoprostu 0,3 mg/ml, kapljicah za oko), ga je treba pri bolnikih s suhimi očmi, pri bolnikih pri katerih je morda roženica poškodovana, in pri bolnikih, ki jemljejo več različnih kapljic, ki vsebujejo benzalkonijev klorid, uporabljati previdno.
The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. 
Pigmentacija se spremeni zaradi povečane vsebnosti melanina v melanocitih in ne zaradi povečanega števila melanocitov.
The dose should not exceed once daily, as more frequent administration may lessen the intraocular pressure lowering effect. 
Odmerjanje naj ne presega dajanja enkrat dnevno, kajti pogostejše vkapanje lahko zmanjša učinek zniževanja očesnega tlaka.
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from available data) adverse reactions are presented according to System Organ Class in Table 1. 
Zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000) in neželeni učinki z neznano pogostnostjo (ni mogoče oceniti iz razpoložljivih podatkov) neželeni učinki so razvrščeni po organskih sistemih v preglednici 1.
Bimatoprost then undergoes oxidation, N-deethylation and glucuronidation to form a diverse variety of metabolites. 
Po oksidaciji, N-deetiletaciji in glukuronidaciji se tvorijo različne oblike presnovkov.
The solution should be used immediately after opening. 
Raztopino morate porabiti takoj po odprtju.
Throw away the single-dose container after you have used it, even if there is some solution left. 
Po uporabi enoodmerni vsebnik zavrzite, četudi niste porabili vse raztopine.
In embryo/foetal developmental studies abortion, but no developmental effects were seen in mice and rats at doses that were at least 860-times or 1700-times higher than the dose in humans, respectively. 
V razvojnih raziskavah na mišjih in podganjih embrijih/fetusih so zabeležili abortuse, vplivov na embrio-fetalni razvoj pri odmerkih, ki so bili 860oz 1700-krat večji od odmerka pri ljudeh, niso opazili.
Investigations common liver function test abnormal 
Preiskave pogosti nenormalni testi jetrne funkcije
Marketing Authorisation Holder and Manufacturer Allergan Pharmaceuticals Ireland Castlebar Road 
Imetnik dovoljenja za promet z zdravilom in izdelovalec Allergan Pharmaceuticals Ireland Castlebar Road
After ocular administration in adults, the systemic exposure of bimatoprost is very low with no accumulation over time. 
Po lokalni uporabi v očesu pri odraslih je sistemska absorpcija bimatoprosta zelo nizka in bimatoprost se v daljšem časovnem obdobju ne kopiči.
Before treatment is initiated, patients should be informed of the possibility of eyelash growth, darkening of the eyelid skin and increased iris pigmentation, since these have been observed during treatment with LUMIGAN. 
Pred začetkom zdravljenjenja je potrebno bolnika obvestiti o možni rasti trepalnic, temnenju kože veke in povečani pigmentaciji irisa, saj so to spremembe, ki so jih opazili med zdravljenjem z zdravilom LUMIGAN.
The change may be more noticeable if you are only treating one eye. 
Omenjene spremembe lahko ostanejo trajne in so opaznejše,če zdravite le eno oko.
LUMIGAN is used to reduce high pressure in the eye. 
LUMIGAN se uporablja za zmanjševanje previsokega očesnega tlaka.
LUMIGAN has not been studied in patients with compromised respiratory function. 
Zdravila LUMIGAN niso preizkušali pri bolnikih z oslabelim delovanjem respiratornega sistema.
The most frequently reported adverse reaction was conjunctival hyperaemia (mostly trace to mild and of a non-inflammatory nature) occurring in 29 % of patients. 
Neželeni učinek, o katerem so poročali najpogosteje, je bila hiperemija veznice (večinoma komaj opazna do blaga in brez vnetja), ki se je pojavila pri 29 % bolnikov.
• Macular oedema (swelling of the retina at the back of the eye which may lead to worsening vision) 
• makularni edem (otekanje mrežnice v očesnem ozadju, kar lahko vodi do poslabšanja vida),
Hypersensitivity reaction including signs and symptoms of eye allergy and allergic dermatitis 
Bolezni imunskega sistema neznana pogostnost preobčutljivostne reakcije, vključno z znaki in simptomi alergije oči in alergijskega dermatitisa
A 12 week (double-masked, randomized, parallel group ) clinical study compared the efficacy and safety of LUMIGAN 0.3 mg/mL single-dose with LUMIGAN 0.3 mg/mL (multi-dose formulation). 
V 12-tedenski (dvojno slepi, randomizirani, s paralelno skupino) klinični študiji so primerjali učinkovitost in varnost zdravila LUMIGAN 0,3 mg/ml (enoodmerna oblika) z učinkovitostjo in varnostjo zdravila LUMIGAN 0,3 mg/ml (večodmerna oblika).
However, this finding is not clinically relevant as systemic exposure for both elderly and young subjects remained very low from ocular dosing. 
Vendar ti rezultati niso klinično pomembni, ker je sistemska izpostavljenost pri očesnem odmerjanju za obe starostni skupini zelo nizka.
If you are worried, talk to your doctor or pharmacist. 
Če ste zaskrbljeni, se pogovorite s svojim zdravnikom ali farmacevtom.
Paediatric population: The safety and efficacy of LUMIGAN in children aged 0 to 18 years has not yet been established. 
Pediatrična populacija: Varnost in učinkovitost zdravila LUMIGAN pri otrocih, starih od 0 do 18 let, še nista bili dokazani.
Mean Cmax and AUC 0-24hrs values were similar on days 7 and 14 at approximately 0.08 ng/ml and 0.09 ng•hr/ml respectively, indicating that a steady bimatoprost concentration was reached during the first week of ocular dosing. 
Povprečne Cmax in AUC 0-24hrs vrednosti so bile podobne na 7. dan približno 0,08 ng/ml in 14. dan približno 0,09 ng•h/ml, kar kaže da je bila ravnotežna koncentracija bimatoprosta dosežena v prvem tednu lokalne uporabe v očesu.
Gently pull down the lower eyelid to form a pocket. 
Nežno povlecite spodnjo veko navzdol, da nastane majhen žepek.
Put the cap back on and close the bottle straight after you have used it. 
Ponovno namestite zaporko in plastenko takoj po uporabi dobro zaprite.
Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers). 
Zniževanje zvišanega očesnega tlaka pri kroničnem glavkomu odprtega zakotja in okularni hipertenziji pri odraslih (v monoterapiji ali kot adjuvantna terapija z antagonisti adrenenergičnih receptorjev beta).
Each pouch contains 10 single-dose containers. 
Vsaka vrečka vsebuje 10 enoodmernih vsebnikov.
Discard the opened single-dose container immediately after use. 
Odprt enoodmerni vsebnik zavrzite takoj po uporabi.
There was no accumulation of bimatoprost in the blood over time and the safety profile was similar in elderly and young patients. 
Varnostni profil je bil podoben pri starejših in mlajših bolnikih.
In very rare cases, some patients with severe damage to the clear layer at the front of the eye (the cornea) have developed cloudy patches on the cornea due to calcium build-up during treatment. 
V zelo redkih primerih je pri nekaterih bolnikih s hudimi poškodbami prozorne plasti na sprednji strani očesa (roženice) prišlo do nastanka motnih zaplat na roženici zaradi kopičenja kalcija med zdravljenjem.
Bimatoprost was not mutagenic or carcinogenic in a series of in vitro and in vivo studies. 
Bimatoprost v številnih študijah in vitro in in vivo ni kazal mutagenega ali karcinogenega delovanja.
Affecting the skin 
Učinki na kožo:
Bimatoprost penetrates the human cornea and sclera well in vitro. 
Bimatoprost in vitro dobro prodira v humano roženico in sklero.
Pack contains 5-single-dose containers in a carton. 
Pakiranje vsebuje 5 enoodmernih vsebnikov v škatli.
The most frequently reported adverse reactions were conjuctival hyperaemia (mostly trace to mild and of a non-inflammatory nature) occurring in 24% of patients, and eye pruritis occurring in 4% of patients. 
Najpogosteje so poročali o hiperemiji veznice (večinoma komaj opazni ali blagi in nevnetni), ki se je pojavila pri 24 % bolnikov, in očesnem pruritusu, ki se je pojavil pri 4 % bolnikov.
Do not use this medicine after the expiry date which is stated on the single-dose container and the carton after the expiry date (EXP):. 
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na enoodmernem vsebniku in škatli poleg datuma izteka roka uporabnosti (EXP).
Opened (1): 
Odprto (1):
At any visit, the mean diurnal IOP values measured over the 12-month study period differed by no more than 1.3 mmHg throughout the day and were never greater than 18.0 mmHg. 
Ob vsaki viziti so se povprečne vrednosti dnevnega očesnega tlaka, merjene v več kot 12 mesečnem času študija, razlikovale za ne več kot 1,3 mmHg preko dneva in niso bile nikoli višje kot 18,0 mmHg.
It belongs to a group of medicines called prostamides. 
Spada v skupino zdravil, imenovanih analogi prostaglandinov.
Please tell your doctor or pharmacist, if: - You have any breathing problems - You have liver or kidney problems - You have had a cataract surgery in the past - You have or have had low blood pressure or low heart rate - You have had a viral infection or inflammation of the eye 
Obvestite svojega zdravnika ali farmacevta, če: - imate kakršnekoli težave z dihanjem, - če imate težave z jetri ali ledvicami, - če ste bili v preteklosti operirani za sivo mreno, - če imate ali ste imeli nizek krvni tlak ali počasen srčni utrip, - če ste imeli virusno okužbo ali vnetje očesa.
During a 12-month pivotal study in adults with LUMIGAN 0.1 mg/ml eye drops, the mean diurnal IOP values measured at any visit over the 12-month study period differed by no more than 1.1 mmHg throughout the day and were never greater than 17.7 mmHg. 
Med 12-mesečno ključno študijo pri odraslih, ki so uporabljali zdravilo LUMIGAN 0,1 mg/ml kapljice za oko, se povprečne dnevne vrednosti očesnega tlaka, izmerjene ob katerem koli obisku v 12-mesečnem obdobju trajanja študije, niso razlikovale za več kot 1,1 mmHg skozi ves dan in nikoli niso bile večje kot 17,7 mmHg.
Turn the bottle upside down and squeeze it to release one drop into each eye that needs treatment. 
Plastenko obrnite s kapalko navzdol in jo stisnite, dokler se ne pojavi ena kapljica, ki jo vkapajte v vsako zdravljeno oko.
Other side effects reported with eye drops containing phosphates In very rare cases, some patients with severe damage to the clear layer at the front of the eye (the cornea) have developed cloudy patches on the cornea due to calcium build-up during treatment. 
Drugi neželeni učinki kapljic za oko, ki vsebujejo fosfate V zelo redkih primerih je pri nekaterih bolnikih s hudimi poškodbami prozorne plasti na sprednji strani očesa (roženice) prišlo do nastanka motnih zaplat na roženici zaradi kopičenja kalcija med zdravljenjem.
No case of overdose has been reported, and is unlikely to occur after ocular administration. 
Ni poročil o primerih prevelikega odmerjanja in ni verjetno, da bi se pojavili pri lokalni uporabi na očeh.
Opened (3): 
Odprto (3):
• Cystoid macular oedema (swelling of the retina within the eye leading to worsening vision) 
• cistoidni makularni edem (otekanje mrežnice v očesu, ki povzroča slabšanje vida),
Opened (2): 
Odprto (2):
Neurobehavioural functions of offspring were not affected. 
Obnašanje mladičev, vezano na njihove živčne in možganske funkcije, ni bilo moteno.
• Hair growth around the eye 
• rast dlak okoli očesa.
Additional adverse reactions reported with LUMIGAN 0.3 mg/ml are presented in Table 2. 
Dodatni neželeni učinki, o katerih so poročali v zvezi z zdravilom LUMIGAN 0,3 mg/ml, so prikazani v preglednici 2.
While there is limited information available on patients with a history of asthma or COPD, there have been reports of exacerbation of asthma, dyspnoea and COPD, as well as reports of asthma, in post marketing experience. 
Čeprav je o bolnikih z anamnezo astme ali kronične obstruktivne pljučne bolezni na voljo malo podatkov, obstajajo poročila o poslabšanju astme, dispneje ali kronične obstruktivne pljučne bolezni in poročila o astmi po prihodu zdravila na trg.
Bimatoprost is moderately distributed into body tissues and the systemic volume of distribution in humans at steady-state was 0.67 l/kg. 
Sistemski volumen porazdelitve v stanju dinamičnega ravnovesja pri ljudeh je bil 0,67 l/kg.
Any unused solution should be discarded immediately after use. 
Neporabljeno raztopino zavrzite takoj po uporabi.
• Swelling of the see-through layer which covers the surface of the eye 
• otekanje prozornega plašča, ki pokriva površino očesa,